These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 27196758)

  • 1. Src as a Therapeutic Target in Biliary Tract Cancer.
    Nam AR; Kim JW; Park JE; Bang JH; Jin MH; Lee KH; Kim TY; Han SW; Im SA; Kim TY; Oh DY; Bang YJ
    Mol Cancer Ther; 2016 Jul; 15(7):1515-24. PubMed ID: 27196758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas.
    Cavalloni G; Peraldo-Neia C; Sarotto I; Gammaitoni L; Migliardi G; Soster M; Marchiò S; Aglietta M; Leone F
    Mol Cancer Ther; 2012 Jul; 11(7):1528-38. PubMed ID: 22452946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance Mechanism against Trastuzumab in HER2-Positive Cancer Cells and Its Negation by Src Inhibition.
    Jin MH; Nam AR; Park JE; Bang JH; Bang YJ; Oh DY
    Mol Cancer Ther; 2017 Jun; 16(6):1145-1154. PubMed ID: 28223426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Src/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/Abl signaling.
    Bieerkehazhi S; Chen Z; Zhao Y; Yu Y; Zhang H; Vasudevan SA; Woodfield SE; Tao L; Yi JS; Muscal JA; Pang JC; Guan S; Zhang H; Nuchtern JG; Li H; Li H; Yang J
    Oncotarget; 2017 Jan; 8(1):1469-1480. PubMed ID: 27903968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of Integrin-Linked Kinase Sensitizes Breast Cancer to SRC Inhibitors.
    Beetham H; Griffith BGC; Murina O; Loftus AEP; Parry DA; Temps C; Culley J; Muir M; Unciti-Broceta A; Sims AH; Byron A; Brunton VG
    Cancer Res; 2022 Feb; 82(4):632-647. PubMed ID: 34921014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
    Remsing Rix LL; Rix U; Colinge J; Hantschel O; Bennett KL; Stranzl T; Müller A; Baumgartner C; Valent P; Augustin M; Till JH; Superti-Furga G
    Leukemia; 2009 Mar; 23(3):477-85. PubMed ID: 19039322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells.
    Vultur A; Buettner R; Kowolik C; Liang W; Smith D; Boschelli F; Jove R
    Mol Cancer Ther; 2008 May; 7(5):1185-94. PubMed ID: 18483306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bosutinib Inhibits EGFR Activation in Head and Neck Cancer.
    Segrelles C; Contreras D; Navarro EM; Gutiérrez-Muñoz C; García-Escudero R; Paramio JM; Lorz C
    Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29933569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints.
    Beeharry N; Banina E; Hittle J; Skobeleva N; Khazak V; Deacon S; Andrake M; Egleston BL; Peterson JR; Astsaturov I; Yen TJ
    Cell Cycle; 2014; 13(14):2172-91. PubMed ID: 24955955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts.
    Messersmith WA; Rajeshkumar NV; Tan AC; Wang XF; Diesl V; Choe SE; Follettie M; Coughlin C; Boschelli F; Garcia-Garcia E; Lopez-Rios F; Jimeno A; Hidalgo M
    Mol Cancer Ther; 2009 Jun; 8(6):1484-93. PubMed ID: 19509264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic implication of HER2 in advanced biliary tract cancer.
    Nam AR; Kim JW; Cha Y; Ha H; Park JE; Bang JH; Jin MH; Lee KH; Kim TY; Han SW; Im SA; Kim TY; Oh DY; Bang YJ
    Oncotarget; 2016 Sep; 7(36):58007-58021. PubMed ID: 27517322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-generation Src/Abl inhibitor bosutinib effectively induces apoptosis in human esophageal squamous cell carcinoma (ESCC) cells via inhibiting Src/Abl signaling.
    Ha YNE; Dai Y; Wufuer D; Pidayi M; Anasihan G; Chen L
    Neoplasma; 2020 Jan; 67(1):54-60. PubMed ID: 31777258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.
    Nam HJ; Im SA; Oh DY; Elvin P; Kim HP; Yoon YK; Min A; Song SH; Han SW; Kim TY; Bang YJ
    Mol Cancer Ther; 2013 Jan; 12(1):16-26. PubMed ID: 23144237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bosutinib Acts as a Tumor Inhibitor via Downregulating Src/NF-κB/Survivin Expression in HeLa Cells.
    Yu L; Guo W; Liu L; Zhang G; Zhang F; Qu Y; Liu Y; Li H; Li H
    Anat Rec (Hoboken); 2019 Dec; 302(12):2193-2200. PubMed ID: 31569304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abrogation of transforming growth factor-β-induced tissue fibrosis in TBRIcaCol1a2Cre transgenic mice by the second generation tyrosine kinase inhibitor SKI-606 (Bosutinib).
    Wermuth PJ; Jimenez SA
    PLoS One; 2018; 13(5):e0196559. PubMed ID: 29718973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma.
    Homsi J; Cubitt CL; Zhang S; Munster PN; Yu H; Sullivan DM; Jove R; Messina JL; Daud AI
    Melanoma Res; 2009 Jun; 19(3):167-75. PubMed ID: 19434004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous inhibition of c-Abl and Src kinases abrogates the exaggerated expression of profibrotic genes in cultured systemic sclerosis dermal fibroblasts.
    Piera-Velazquez S; Jimenez SA
    Clin Exp Rheumatol; 2018; 36 Suppl 113(4):36-44. PubMed ID: 30277861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
    Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
    Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Jab1 Silencing Inhibits Proliferation and Sensitizes to Cisplatin in Biliary Tract Cancer.
    Nam AR; Kim JW; Park JE; Bang JH; Jin MH; Oh DY; Bang YJ
    Cancer Res Treat; 2019 Jul; 51(3):886-900. PubMed ID: 30282449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SKI-606, an Src inhibitor, reduces tumor growth, invasion, and distant metastasis in a mouse model of thyroid cancer.
    Kim WG; Guigon CJ; Fozzatti L; Park JW; Lu C; Willingham MC; Cheng SY
    Clin Cancer Res; 2012 Mar; 18(5):1281-90. PubMed ID: 22271876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.